Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.22 | N/A | +7.63% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.22 | N/A | +7.63% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market environment. They remain focused on their strategic initiatives while navigating short-term challenges.
Management highlighted ongoing challenges in revenue generation.
They emphasized a focus on long-term strategies despite current losses.
Alnylam Pharmaceuticals reported a loss that was slightly better than expected, which led to a modest decline in the stock price. The lack of revenue figures and guidance may have contributed to investor caution. Overall, the company is facing challenges but remains committed to its long-term goals.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MPLX LP
Apr 30, 2018